Jaqueline Amorim’s six-month suspension delays a submission-heavy strawweight run

Jaqueline Amorim’s next fight will have to wait, halting the momentum of one of the UFC strawweight division’s most submission-dependent contenders.

MMA Mania reported that Amorim tested positive for ostarine in out-of-competition samples collected July 29 and Aug. 17, 2026; the findings were combined into one violation after investigators determined they were consistent with low-level supplement contamination rather than intentional use, resulting in a six-month suspension retroactive to the second test and an eligibility date of Feb. 17, 2027. The investigation also found no indication of a significant performance advantage.

That ruling changes Amorim’s availability, but it does not immediately create a wager. She has no booked opponent, no attached market and no model projection. The betting relevance sits in what the interruption does to an unusually concentrated finishing profile—and which questions must be answered once matchmaking resumes.

The suspension interrupts a defined finishing pattern

Amorim is 11-2 overall and 5-2 across seven archived UFC bouts. All five of those UFC wins ended inside the distance: four by submission and one by knockout or technical knockout. She has not recorded a decision victory in that sample, and neither of her two UFC losses ended by stoppage.

Her recent sequence makes the mechanism clear. Amorim submitted Cory McKenna in the first round, Vanessa Demopoulos in the first, Polyana Viana in the second and Loma Lookboonmee in the first. The only break in that run was a three-round unanimous-decision loss to Mizuki in October 2025.

The 100% finish rate on her UFC wins is notable, but it belongs to a five-win sample and should be treated as such. It does not establish that every favorable matchup will finish. It does show that Amorim’s successful route has consistently involved creating decisive exchanges rather than banking rounds.